Matilda Anneback
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matilda Anneback has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Aimee N. Di Marco
Department of Endocrine Surgery Imperial College Healthcare NHS Trust Hammersmith Hospital London London UK
1 shared publication - Andreas Karakatsanis
Department of Surgical Sciences, Uppsala University , Uppsala
1 shared publication - Anna Henriksson
Department of Health Sciences, Innovation and Design, Mälardalen University, Västerås, Sweden
1 shared publication - Anne-Sophie Mazzoni
Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
1 shared publication - Birgitta Johansson
Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden
1 shared publication David Kudrén
Department of Oncology Södersjukhuset Stockholm Sweden
1 shared publication
Latest Publications
- Open Access
- 11 April 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (8) , 2071-2076
Five Advances in the Last 50 Years That Have Impacted Endocrine Surgery
- 11 April 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (8) , 2071-2076
Open AccessFive Advances in the Last 50 Years That Have Impacted Endocrine Surgery
- 2 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23784
Effects of heavy‐load strength training during (neo‐)adjuvant chemotherapy on muscle strength, muscle fiber size, myonuclei, and satellite cells in women with breast cancer
To investigate the effects of heavy‐load strength training during (neo‐)adjuvant chemotherapy in women with breast cancer on muscle strength, body composition, muscle fiber size, satellite cells, and myonuclei. Women with stage I‐III breast cancer were randomly assigned to a strength training group (ST, n = 23) performing supervised heavy‐load strength training twice a week during chemotherapy, or a usual care control group (CON, n = 17). Muscle strength and body composition were measured and biopsies from m. vastus lateralis collected before the first cycle of chemotherapy (T0) and after chemotherapy and training (T1). Muscle strength increased significantly more in ST than in CON in chest‐press (ST: +10 ± 8%, p < .001, CON: −3 ± 5%, p = .023) and leg‐press (ST: +11 ± 8%, p < .001, CON: +3 ± 6%, p = .137). Both groups reduced fat‐free mass (ST: −4.9 ± 4.0%, p < .001, CON: −5.2 ± 4.9%, p = .004), and increased fat mass (ST: +15.3 ± 16.5%, p < .001, CON: +16.3 ± 19.8%, p = .015) with no significant differences between groups. No significant changes from T0 to T1 and no significant differences between groups were observed in muscle fiber size. For myonuclei per fiber a non‐statistically significant increase in CON and a non‐statistically significant decrease in ST in type I fibers tended ( p = .053) to be different between groups. Satellite cells tended to decrease in ST (type I: −14 ± 36%, p = .097, type II: −9 ± 55%, p = .084), with no changes in CON and no differences between groups. Strength training during chemotherapy improved muscle strength but did not significantly affect body composition, muscle fiber size, numbers of satellite cells, and myonuclei compared to usual care.
- 2 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23784
Effects of heavy‐load strength training during (neo‐)adjuvant chemotherapy on muscle strength, muscle fiber size, myonuclei, and satellite cells in women with breast cancer
To investigate the effects of heavy‐load strength training during (neo‐)adjuvant chemotherapy in women with breast cancer on muscle strength, body composition, muscle fiber size, satellite cells, and myonuclei. Women with stage I‐III breast cancer were randomly assigned to a strength training group (ST, n = 23) performing supervised heavy‐load strength training twice a week during chemotherapy, or a usual care control group (CON, n = 17). Muscle strength and body composition were measured and biopsies from m. vastus lateralis collected before the first cycle of chemotherapy (T0) and after chemotherapy and training (T1). Muscle strength increased significantly more in ST than in CON in chest‐press (ST: +10 ± 8%, p < .001, CON: −3 ± 5%, p = .023) and leg‐press (ST: +11 ± 8%, p < .001, CON: +3 ± 6%, p = .137). Both groups reduced fat‐free mass (ST: −4.9 ± 4.0%, p < .001, CON: −5.2 ± 4.9%, p = .004), and increased fat mass (ST: +15.3 ± 16.5%, p < .001, CON: +16.3 ± 19.8%, p = .015) with no significant differences between groups. No significant changes from T0 to T1 and no significant differences between groups were observed in muscle fiber size. For myonuclei per fiber a non‐statistically significant increase in CON and a non‐statistically significant decrease in ST in type I fibers tended ( p = .053) to be different between groups. Satellite cells tended to decrease in ST (type I: −14 ± 36%, p = .097, type II: −9 ± 55%, p = .084), with no changes in CON and no differences between groups. Strength training during chemotherapy improved muscle strength but did not significantly affect body composition, muscle fiber size, numbers of satellite cells, and myonuclei compared to usual care.